DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM

GeorgeH Mccracken, DuaneL Dowell, FlorenceN Marshall

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.

Original languageEnglish (US)
Pages (from-to)1146-1149
Number of pages4
JournalThe Lancet
Volume297
Issue number7710
DOIs
StatePublished - Jun 5 1971

Fingerprint

Antitoxins
Tetanus
Tetanus Antitoxin
Horses
Immunoglobulins
Hospital Mortality
Survivors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM. / Mccracken, GeorgeH; Dowell, DuaneL; Marshall, FlorenceN.

In: The Lancet, Vol. 297, No. 7710, 05.06.1971, p. 1146-1149.

Research output: Contribution to journalArticle

Mccracken, GeorgeH ; Dowell, DuaneL ; Marshall, FlorenceN. / DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM. In: The Lancet. 1971 ; Vol. 297, No. 7710. pp. 1146-1149.
@article{c4acbd944cff46f4976b862897174676,
title = "DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM",
abstract = "130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.",
author = "GeorgeH Mccracken and DuaneL Dowell and FlorenceN Marshall",
year = "1971",
month = "6",
day = "5",
doi = "10.1016/S0140-6736(71)91659-X",
language = "English (US)",
volume = "297",
pages = "1146--1149",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7710",

}

TY - JOUR

T1 - DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM

AU - Mccracken, GeorgeH

AU - Dowell, DuaneL

AU - Marshall, FlorenceN

PY - 1971/6/5

Y1 - 1971/6/5

N2 - 130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.

AB - 130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.

UR - http://www.scopus.com/inward/record.url?scp=0015211628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015211628&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(71)91659-X

DO - 10.1016/S0140-6736(71)91659-X

M3 - Article

VL - 297

SP - 1146

EP - 1149

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7710

ER -